TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29476238

Group type: EXPERIMENTAL
Intervention: Low calorie, high polyphenol cranberry extract beverage (CEB)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 28040386

Group type: EXPERIMENTAL
Intervention: New two-thumb technique (nTTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard two finger technique (TFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard two thumb technique (TTHT)
Number of subjects: 0
Study: 25711320

Group type: EXPERIMENTAL
Intervention: Standard consent form
Number of subjects: 4473

Group type: COMPARATOR
Intervention: Concise consent form
Number of subjects: 4473
Study: 24390522

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie-restricted diet
Number of subjects: 0
Study: 22465047

Group type: EXPERIMENTAL
Intervention: 0.006 mg/kg/day of GH subcutaneously (group A, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (group B, n=60)
Number of subjects: 120
Study: 19204509

Group type: EXPERIMENTAL
Intervention: HBOC-201 (up to ten 30 g Hb units)
Number of subjects: 688

Group type: COMPARATOR
Intervention: RBC (up to 9 units)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: HBOC-201
Number of subjects: 688

Group type: COMPARATOR
Intervention: RBC
Number of subjects: 688
Study: 17302656

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 524

Group type: COMPARATOR
Intervention: Enhanced specialty referral care
Number of subjects: 524
Study: 15059636

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU daily for 6 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11588286

Group type: EXPERIMENTAL
Intervention: Video role play with structured feedback
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 132
Study: 10189388

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 66
Study: 7538815

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at 1.0, 2.5, 3.75, and 5.0 micrograms/kg/d
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at 5.0 micrograms/kg/d
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at 3.75 micrograms/kg/d
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) maintenance therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6)
Number of subjects: 22
Study: 2177394

Group type: EXPERIMENTAL
Intervention: Carboplatin (CP) 167‐436 mg/m2 by intravenous infusion, repeated every 4 weeks, 2‐4 cycles
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy containing CP (CE: CP + VP ‐ 16)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Combination chemotherapy containing DDP (PE: DDP + VP ‐ 16)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy containing CP (CAC: CP + adriamycin + cyclophosphamide)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Combination chemotherapy containing DDP (PAC: DDP + adriamycin + cyclophosphamide)
Number of subjects: 243
Study: 7406654

Group type: EXPERIMENTAL
Intervention: Methadyl acetate administered on Friday, starting dose identical to previously established methadone dose, flexible thereafter.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Daily methadone comparison group.
Number of subjects: 136
Study: 30229398

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) administered to elderly renal transplant recipients
Number of subjects: 44
Study: 27831462

Group type: EXPERIMENTAL
Intervention: Physical exercise program (20 sessions of strengthening, balance, and walking over 4 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Social interaction sessions (equivalent duration and frequency to EG, without physical exercise)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Physical exercise program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Social interaction sessions
Number of subjects: 160
Study: 25850024

Group type: EXPERIMENTAL
Intervention: Hybrid-variable priority training (HVT) program for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 28
Study: 24124930

Group type: EXPERIMENTAL
Intervention: Nutritional and eating education for 6 months
Number of subjects: 162
Study: 21070781

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day (once daily)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Mesalamine 4.5 g/day
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg/day (3 times daily)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Budesonide vs Mesalamine
Number of subjects: 309
Study: 19092729

Group type: EXPERIMENTAL
Intervention: Valdecoxib and parecoxib (40 mg IV every 6 hours on day one postoperative)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 116
Study: 17712135

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 1069
Study: 15448515

Group type: EXPERIMENTAL
Intervention: Video-assisted fiberoptic intubation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional fiberoptic intubation
Number of subjects: 20
Study: 11426006

Group type: EXPERIMENTAL
Intervention: Whole-body MR imaging with real-time true fast imaging with steady-state precession
Number of subjects: 5

Group type: COMPARATOR
Intervention: Thoracic and abdominal helical computed tomography
Number of subjects: 5
Study: 11218929

Group type: EXPERIMENTAL
Intervention: Waterless hand preparation (HP) containing 61% ethyl alcohol, 1% CHG, and emollients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional surgical scrub (TSS)
Number of subjects: 20
Study: 9232709

Group type: EXPERIMENTAL
Intervention: Insulin therapy in health care centre
Number of subjects: 28

Group type: COMPARATOR
Intervention: Insulin therapy in day-care clinic
Number of subjects: 28
Study: 8358075

Group type: EXPERIMENTAL
Intervention: New flavoured PEG solution for gut lavage
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard preparation (2‐day semi‐liquid diet, laxatives and cleansing enemas)
Number of subjects: 160
Study: 3313678

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) 1500 mg slow-release/day (Pentasa)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 67
Study: 2175687

Group type: EXPERIMENTAL
Intervention: Lipiodol Ultra Fluid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Urografin 290
Number of subjects: 60
Study: 1062910

Group type: EXPERIMENTAL
Intervention: 200 mg of ferrous iron daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31094798

Group type: EXPERIMENTAL
Intervention: Glidescope + fiberscope
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard Glidescope
Number of subjects: 160
Study: 27376411

Group type: EXPERIMENTAL
Intervention: eCBT (exposure-based cognitive behavioural therapy)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Genetic variants
Number of subjects: 181

Group type: COMPARATOR
Intervention: Gene expression
Number of subjects: 181
Study: 25238699

Group type: COMPARATOR
Intervention: Mineral oil (control group; n = 17)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olive oil (n = 16)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (n = 17)
Number of subjects: 50
Study: 24939817

Group type: EXPERIMENTAL
Intervention: 24h pretreatment with dexamethasone (0.5 mg/kg/dose, q6h, total of six doses; n = 66)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 6h pretreatment with dexamethasone (total of three doses; n = 58)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 24h pretreatment with dexamethasone
Number of subjects: 124

Group type: COMPARATOR
Intervention: 6h pretreatment with dexamethasone
Number of subjects: 124
Study: 22214352

Group type: EXPERIMENTAL
Intervention: Active inspiratory exercise programme for eight months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo exercise programme for the first four months followed by active exercise for the second four-month period
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inspiratory exercise
Number of subjects: 26
Study: 19776028

Group type: EXPERIMENTAL
Intervention: Propofol/paravertebral anaesthesia‐analgesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sevoflurane general anaesthesia with opioid analgesia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 17264136

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and management consultations
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 345

Group type: COMPARATOR
Intervention: External comparison group (no GEM teams)
Number of subjects: 345
Study: 15140531

Group type: EXPERIMENTAL
Intervention: Early initiation of Tirofiban
Number of subjects: 507

Group type: COMPARATOR
Intervention: Late initiation of Tirofiban
Number of subjects: 507
Study: 12460127

Group type: EXPERIMENTAL
Intervention: Manual-guided outpatient treatments
Number of subjects: 600

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 600
Study: 9806127

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg daily, n = 23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: L-EE (1 tablet containing 0.05 mg + 2.5 mg, 3 times daily, n = 25)
Number of subjects: 48
Study: 7617153

Group type: EXPERIMENTAL
Intervention: Right visual field for categorical judgements
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Left visual field for coordinate judgements
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Right-handed subjects
Number of subjects: 104

Group type: COMPARATOR
Intervention: Left-handed subjects
Number of subjects: 104
Study: 2536211

Group type: EXPERIMENTAL
Intervention: Extruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonextruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Number of subjects: 0
Study: 344107

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) and BCG
Number of subjects: 159
Study: 31987796

Group type: EXPERIMENTAL
Intervention: Synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subspecies lactis BB-12; n=55)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (n=49)
Number of subjects: 104
Study: 30772827

Group type: EXPERIMENTAL
Intervention: E‐cigarette advertisement with a fake warning
Number of subjects: 775

Group type: COMPARATOR
Intervention: Other e‐cigarette advertisements (control)
Number of subjects: 775
Study: 28099236

Group type: EXPERIMENTAL
Intervention: Perfluorohexane treatment (endotracheal instillation) in addition to conventional treatment.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional treatment (anti-infection, nutritional support, antishock measures, and supportive treatment).
Number of subjects: 23
Study: 25847401

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (two times a day added to a conventional diet)
Number of subjects: 28
Study: 23521170

Group type: EXPERIMENTAL
Intervention: Topical ketamine (0.4 ml, 20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical tramadol (0.8 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (5 ml saline)
Number of subjects: 60
Study: 22039471

Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg/m², given twice two weeks apart
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 30
Study: 19040308

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 17524529

Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed four-fold increase in rSBA
Number of subjects: 0
Study: 15631963

Group type: EXPERIMENTAL
Intervention: Internet questionnaire (n=221)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Mailed questionnaire (n=221)
Number of subjects: 442
Study: 11712036

Group type: EXPERIMENTAL
Intervention: Commercial zinc pyrithione (ZPT) shampoo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9642594

Group type: EXPERIMENTAL
Intervention: MicroVisc Plus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healon GV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Healon GV/MicroVisc Plus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healon/MicroVisc
Number of subjects: 100
Study: 7808206

Group type: EXPERIMENTAL
Intervention: Rating scale
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 40
Study: 2783697

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amitryptiline
Number of subjects: 28
Study: 1097220

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study: 31577792

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (up to 14 text messages during pregnancy and after delivery)
Number of subjects: 2515

Group type: COMPARATOR
Intervention: Control group (no text messaging intervention)
Number of subjects: 2515
Study: 30072745

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Number of subjects: 375

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 375
Study: 24828795

Group type: EXPERIMENTAL
Intervention: Personal Respiratory Sampling Test (PRST)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional Portacount fit‐test method
Number of subjects: 84
Study: 23836508

Group type: EXPERIMENTAL
Intervention: Video messages from a media campaign
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1677
Study: 22770436

Group type: EXPERIMENTAL
Intervention: High-intensity disease management (HDM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 19554196

Group type: EXPERIMENTAL
Intervention: Respimat Soft Mist Inhaler (SMI) (200 or 400 microg bd)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Turbuhaler dry powder inhaler (400 microg bd)
Number of subjects: 153
Study: 17549293

Group type: EXPERIMENTAL
Intervention: AHF (High Purity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biostate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both AHF (High Purity) and Biostate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AHF (High Purity) and Biostate
Number of subjects: 12
Study: 15179342

Group type: EXPERIMENTAL
Intervention: Diluted cardioplegia (4:1 blood to crystalloid ratio; n=25)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Minicardioplegia (undiluted; n=34)
Number of subjects: 59
Study: 12243915

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 5 years
Number of subjects: 7152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7152

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 7152
Study: 9519420

Group type: EXPERIMENTAL
Intervention: Calcium oxalate crystalluria in stone formers (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Calcium oxalate crystalluria in control subjects (n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Crystalluric subjects (n=7)
Number of subjects: 22
Study: 7827647

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study: 2817624

Group type: EXPERIMENTAL
Intervention: Oxygen (O2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 9
Study: 1119396

Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.5 mg digoxin daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control patients (no digoxin)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Variable doses of digoxin (0 to 0.75 mg)
Number of subjects: 21
Study: 30361077

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation training
Number of subjects: 44

Group type: COMPARATOR
Intervention: General trunk exercises
Number of subjects: 44
Study: 27256575

Group type: EXPERIMENTAL
Intervention: Post-intervention assessment completion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reach and representativeness
Number of subjects: 0
Study: 25637007

Group type: EXPERIMENTAL
Intervention: Topical coconut oil applications
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no coconut oil applications)
Number of subjects: 258
Study: 23941633

Group type: EXPERIMENTAL
Intervention: Goal management intervention (psycho-educational program with six group meetings and homework assignments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goal management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study: 21397384

Group type: EXPERIMENTAL
Intervention: New course design (interventional group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard course design (control group)
Number of subjects: 66
Study: 18596389

Group type: EXPERIMENTAL
Intervention: Sorafenib as a single-agent therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib in combination with carboplatin and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) plus sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temozolomide plus sorafenib
Number of subjects: 0
Study: 16671363

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) immersion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no VR exposure)
Number of subjects: 20
Study: 12954304

Group type: EXPERIMENTAL
Intervention: Silicone CeeOn Edge IOL
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acrylate AcrySof IOL
Number of subjects: 78
Study: 11095456

Group type: EXPERIMENTAL
Intervention: Weekly GH dose (natural log transformation)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Oxandrolone treatment
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Distance between height and target height (SD score)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Body weight SD
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Number of GH injections per week
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Karyotype
Number of subjects: 843
Study: 8641508

Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 3 after OPU
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 5 after OPU
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 3 with exclusively unfragmented embryos
Number of subjects: 643

Group type: COMPARATOR
Intervention: Embryo transfer on day 3 with embryos containing > 0% and < 20% fragments
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 5 with one or more cavitating embryos
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 5 with morula stages showing signs of starting blastulation
Number of subjects: 643

Group type: COMPARATOR
Intervention: Embryo transfer on day 5 with embryos not reaching blastulation stage
Number of subjects: 643
Study: 8500245

Group type: EXPERIMENTAL
Intervention: Patient self-assessed quality of life questionnaire score
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: NYHA functional class
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Exercise performance
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Peak heart rate
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Elevated venous pressure and cardiomegaly
Number of subjects: 804
Study: 3103416

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (2 mg/kg daily of elemental zinc supplement as acetate)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 32
Study: 30524185

Group type: EXPERIMENTAL
Intervention: Curettage plus NCH gel (intervention group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Curettage alone (control group)
Number of subjects: 60
Study: 25344629

Group type: EXPERIMENTAL
Intervention: High cocoa flavanol-containing diet for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low cocoa flavanol-containing diet for 3 months
Number of subjects: 0
Study: 22012196

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVIG + prednisolone (PSL) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVIG therapy
Number of subjects: 0
Study: 20458454

Group type: EXPERIMENTAL
Intervention: Supportive intervention scheme
Number of subjects: 2398

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2398
Study: 18519295

Group type: EXPERIMENTAL
Intervention: Preventive home visits (PHVs) - two visits per year over 2 years
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Preventive home visits (PHVs)
Number of subjects: 196
Study: 15750457

Group type: EXPERIMENTAL
Intervention: TdcP-IPV
Number of subjects: 194

Group type: COMPARATOR
Intervention: DTacP plus OPV
Number of subjects: 194
Study: 12110423

Group type: EXPERIMENTAL
Intervention: Menatetrenone (MK-4) 45 mg daily for 12 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 120
Study: 10334139

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP); total dosage, 1,000 microg/d
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 7487579

Group type: EXPERIMENTAL
Intervention: Blindfolded
Number of subjects: 34

Group type: COMPARATOR
Intervention: Blind individuals
Number of subjects: 34